13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE Filed 2025-09-30 Event 2025-09-29 SEC 0001104659-25-095007 →

VAN HERK INVESTMENTS B.V. → ProQR Therapeutics N.V. PRQR

Stake: 13.60% Shares: 14,329,690 CUSIP: N71542109 Class: Ordinary Shares, nominal value Euro 0.04 per share
Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 17/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: +0.0%
  • Filer track record (3 filings): 0% 90d win rate, +0.0% 90d edge
  • High conviction ownership stake (13.6%)
  • Held by 1 tracked 13F institutional manager
  • Moderate short days-to-cover (3.0 DTC)

Item 4 — Purpose of Transaction

Item 4 of the Schedule 13D is amended by adding the following: The Reporting Persons acquired the Ordinary Shares reported herein for investment purposes in the ordinary course of business. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Ordinary Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in communications with management and the board of directors of the Issuer, engaging in discussions with stockholders of the Issuer or other third parties about the Issuer and the Reporting Persons' investment, including potential business combinations or dispositions involving the Issuer or certain of its businesses, making recommendations or proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition), potential business combinations or dispositions involving the Issuer or certain of its businesses, or suggestions for improving the Issuer's financial and/or operational performance, purchasing additional Ordinary Shares, selling some or all of their Ordinary Shares, engaging in short selling of or any hedging or similar transaction with respect to the Ordinary Shares, including swaps and other derivative instruments, or changing their intention with respect to any and all matters referred to in Item 4.

Cross-References

Insider Activity (last 365d)
1 transaction
1 buys · 0 sales · 0 awards/exercises
Issuer Cluster
5 13D/G filings on this issuer
4 other filings besides this one
Filer Track Record
7 filings by this filer
6 other filings in the data moat
Short Interest · settle 2026-10-15
DTC 3.02
2,909,335 shares short · +1.5% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers
1 holder · $1.64M
Point72 Asset Mgmt

Post-Filing Returns · since 2025-09-29 on PRQR

+1 day
0.0%
+5 days
0.0%
+30 days
0.0%
+60 days
0.0%
+90 days
0.0%
+180 days
0.0%

Anchor price 1.66 on closest trading day on/after 2025-09-29. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-07-09 de Boer Daniel Anton director, officer Buy 150,000 $1.74 $261K

Other 13D/G Filings on ProQR Therapeutics N.V.

FiledFormFilerStakeShares
2026-07-29 SCHEDULE 13D/A VAN HERK INVESTMENTS B.V. — 15,384,250 view →
2026-07-29 SCHEDULE 13G Aberdeen Group plc — — view →
2026-06-30 SCHEDULE 13D/A VAN HERK INVESTMENTS B.V. — 15,384,250 view →
2026-06-03 SCHEDULE 13D/A VAN HERK INVESTMENTS B.V. 14.60% 15,384,250 view →

Other Filings by VAN HERK INVESTMENTS B.V.

FiledFormIssuerStakeShares
2026-07-29 SCHEDULE 13D/A ProQR Therapeutics N.V. — 15,384,250 view →
2026-06-30 SCHEDULE 13D/A ProQR Therapeutics N.V. PRQR — 15,384,250 view →
2026-06-03 SCHEDULE 13D/A ProQR Therapeutics N.V. PRQR 14.60% 15,384,250 view →
2018-03-20 SC Ablynx NV — — view →
2018-03-13 SC Ablynx NV — — view →
2018-02-27 SC Ablynx NV — — view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →